Brazil's Anti-Smoking Project in Amazon: Progress and Challenges

Regulations by 2FIRSTS.ai
May.16.2024
Brazil's Anti-Smoking Project in Amazon: Progress and Challenges
Representatives from Amazonas met at FCecon to discuss advancing the tobacco control project, aiming to reduce smoking rates.

According to Brazilian media reports on May 15th, representatives from the local government of Amazonas and coordinators of national and state-level tobacco control programs met at the Amazonas State Cancer Control Foundation (FCecon) to discuss how to further advance the project. The meeting was attended by Gerson Mourão, director of the Amazonas State Cancer Control Foundation, and representatives from the Amazonas State Health Department (SES-AM).

 

The National Tobacco Control Program (PNCT) is a joint initiative of the Brazilian Ministry of Health and the Brazilian National Cancer Institute (Inca) with a 20-year history. The aim of the program is to reduce smoking rates and smoking- related death rates. In the Amazon region, these activities are primarily carried out by the Amazonas State Cancer Control Center Foundation (FCecon).

 

Aristóteles Alencar, the state coordinator of the Amazonas Tobacco Control Program, stated that Amazonas ranked third in the country for the number of tobacco consumers who quit smoking, achieving remarkable results. He mentioned that the visit from the team of the Brazilian National Cancer Institute (Inca) was to understand the effective actions that have led to Amazonas reaching high quit smoking rates.

 

He pointed out, "Despite the vast expanse of the region and the many logistical challenges, the Brazilian National Cancer Institute (Inca) chose the Amazonas state as its research subject because we have achieved the lowest smoking rates nationwide. Our model can be replicated in other places. The key factors to success include the Amazonas State Cancer Control Center Foundation disseminating information to the public, as well as collaborating with the city and state education departments (Seduc and Semed) to host events promoting anti-smoking campaigns with children, and so on.

 

Alanaca added that, currently, the project is in its second phase. The project aims to expand anti-smoking activities to other areas and places a strong emphasis on understanding the unique environmental factors of each location in order to improve the health of the local population. The purpose of this meeting is to gather the strength of various organizations and individuals to enhance the effectiveness and sustainability of the anti-smoking project. The meeting also aims to raise awareness among regional representatives of the significant economic costs of the diseases and loss of life caused by smoking.

 

This type of epidemic has caused losses of up to 125 billion reais to our country, and we can only recover 10% of that amount from taxes. The amount itself is already unacceptable," expressed Alencar.

 

In addition, consultants Lucas Cabral and Érica Cavalcante from the Brazilian National Cancer Institute emphasized the efforts of institutions such as the Brazilian Ministry of Health (MS) in safeguarding public health and combating tobacco consumption.

 

Lucas Cabral stated: "We need to learn and understand from ourselves as the foundation for improving and integrating public policies, which are implemented by the Brazilian Ministry of Health and the Brazilian National Cancer Institute.

 

The project aims to ensure the strength of domestic tobacco control actions while also taking sustainability into consideration.

 

Due to limited health budget, we first chose five states, one in each region. Now, through discussions with state coordinating bodies, we hope to understand their weaknesses and strengths, and together advance anti-smoking campaigns," explained Kaval Kant.

 

Next, a team from the Brazilian National Cancer Institute and local partners will hold a meeting with professionals responsible for assisting smokers in quitting. They will discuss topics such as tobacco prevention, creating smoke-free environments, and treatment for e-cigarette use.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14